Team Veye July 10, 2026

Mesoblast Limited’s Continued Growth Underpins First Full Year Net Revenue of US$115M

Get your Free Report on Top 5 ASX stocks for 2025

Mesoblast Limited (ASX: MSB) has announced on 10 July 2026 that Ryoncil delivered net revenue of US$36 million for the quarter ended 30 June 2026, bringing full year net revenue to US$115 million.

The update signals continued commercial momentum for Mesoblast’s lead product after launch. The company noted that Ryoncil’s uptake has been strong and that the revenue has already exceeded initial projections which reflects growing adoption across major U.S. pediatric centers.

Management also pointed to a solid capital position and said operations remain well funded through revenue growth.

Ryoncil is the first mesenchymal stromal cell therapy to receive FDA approval for any indication, and it remains the only authorized treatment for children under 12 with steroid‑refractory acute graft‑versus‑host disease. This distinction positions the therapy uniquely within a niche but critical market, supporting both near‑term commercial momentum and the credibility of Mesoblast’s broader pipeline over the long run.

Mesoblast also framed the revenue update within a broader strategic context. The company reported that the new five year facility has created additional flexibility allowing it to direct resources toward label expansion and other blockbuster opportunities. That suggests the cash flow profile from Ryoncil may begin supporting broader development priorities rather than only launch execution.

The announcement is a clear positive for investors because it combines revenue growth, operational progress and confirmation that the product is gaining momentum in a specialized U.S. pediatric market.

(Source: Company Announcement)

Disclaimer

Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.

Name

Email address

Phone

By providing your details, you agree to Veye’s Terms & Conditions, Privacy Policy, and Financial Services Guide and to receive marketing offers by email, text message or phone call from us or our agents until you opt out. Before you access our services, please read the Financial Service Guide available here.